Multifaceted transforming growth factor-beta (TGFβ) signalling in glioblastoma

Joanna L. Birch, Barry J. Coull, Lindsay C. Spender, Courtney Watt, Alice Willison, Nelofer Syed, Anthony J. Chalmers, M. Kismet Hossain-Ibrahim, Gareth J. Inman (Lead / Corresponding author)

    Research output: Contribution to journalReview articlepeer-review

    21 Citations (Scopus)


    Glioblastoma (GBM) is an aggressive and devastating primary brain cancer which responds very poorly to treatment. The average survival time of patients is only 14–15 months from diagnosis so there is a clear and unmet need for the development of novel targeted therapies to improve patient outcomes. The multifunctional cytokine TGFβ plays fundamental roles in development, adult tissue homeostasis, tissue wound repair and immune responses. Dysfunction of TGFβ signalling has been implicated in both the development and progression of many tumour types including GBM, thereby potentially providing an actionable target for its treatment. This review will examine TGFβ signalling mechanisms and their role in the development and progression of GBM. The targeting of TGFβ signalling using a variety of approaches including the TGFβ binding protein Decorin will be highlighted as attractive therapeutic strategies.

    Original languageEnglish
    Article number109638
    Number of pages12
    JournalCellular Signalling
    Early online date19 Apr 2020
    Publication statusPublished - Aug 2020


    • Decorin
    • Glioblastoma
    • Transforming growth factor beta

    ASJC Scopus subject areas

    • Cell Biology


    Dive into the research topics of 'Multifaceted transforming growth factor-beta (TGFβ) signalling in glioblastoma'. Together they form a unique fingerprint.

    Cite this